Analyst Debanjana Chatterjee from JonesTrading maintained a Buy rating on Opus Genetics and keeping the price target at $6.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Debanjana Chatterjee has given her Buy rating due to a combination of factors related to the promising developments in Opus Genetics’ ongoing clinical trials. The initial data from the pediatric cohort in the OPGx-LCA5 trial has shown a positive safety profile and significant improvements in visual function just one month after treatment. The upcoming three-month data update is expected to provide further insights into the sustainability and depth of these improvements across key efficacy parameters such as the multi-luminance orientation and mobility test, full-field stimulus test, and best corrected visual acuity.
Chatterjee is particularly optimistic about the potential clinical significance of the expected improvements, noting that even modest gains in these parameters can be highly meaningful for patients with inherited retinal diseases. Additionally, the analyst is closely monitoring the safety profile, particularly any ocular or systemic side effects, to ensure the treatment’s overall benefit. The small cohort size will also be considered to assess the baseline severity and potential benefits for each patient, which further supports the Buy rating for Opus Genetics’ stock.